Eli Samaha has reported the sale of approximately 9.2 million shares of Theravance Biopharma, Inc. in a recent filing. This transaction is significant as it follows the company's merger with Zymeworks Inc., which has transformed Theravance into a wholly owned subsidiary of Zymeworks. The sale indicates a strategic shift for Samaha, who is a major stakeholder in the company.

Samaha's filing, dated November 16, 2026, reveals that the shares were sold at a price of $17.00 each on September 23, 2026. This sale comes as part of the merger agreement that was finalized earlier this year. In the filing, Samaha noted that the shares he held were canceled and converted into cash and contingent value rights as part of the merger.

Background

Theravance Biopharma, Inc. is a company focused on developing innovative medicines for serious diseases. The firm operates within the pharmaceutical preparations sector, classified under the SIC code 2834. Recent filings indicate that Theravance has undergone significant changes, including its merger with Zymeworks Inc., which has now positioned it under a new parent company.

What the Filing Says

The Form 4 filing states, "On September 23, 2026, pursuant to that certain Agreement and Plan of Merger... the Issuer became a wholly owned subsidiary of Parent... each ordinary share... held by the reporting person... was cancelled and converted into the right to receive... $17.00 in cash... and one contingent value right." This highlights the financial implications of the merger for shareholders, including Samaha.

Impact

This transaction may affect various stakeholders, including investors, analysts, and competitors in the pharmaceutical industry. As Samaha is a significant shareholder, his actions might influence market perceptions of Theravance's stability and future performance. The merger with Zymeworks is expected to reshape the competitive landscape within the pharmaceutical preparations sector.

What's Next

The filing does not say what happens next.